DK0705902T3 - 17q-koblet bryst- og ovariecancerprædisponeringsgen - Google Patents

17q-koblet bryst- og ovariecancerprædisponeringsgen

Info

Publication number: DK0705902T3
Authority: DK; Denmark
Prior art keywords: ovarian cancer; breast; relates; human; gene
Prior art date: 1994-08-12

Application number

DK95305601T

Other languages

English (en)

Inventor

Mark H Skolnick

David E Goldgar

Yoshio Miki

Jeff Swensen

Alexander Kamb

Keith D Harshman

Donna M Shattuck-Eidens

Sean V Tavtigian

Roger W Wiseman

P Andrew Futreal

Original Assignee

Univ Utah Res Found

Us Health

Myriad Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-12

Filing date

1995-08-11

Publication date

2002-03-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0705902(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-07 Priority claimed from US08/483,554 external-priority patent/US5747282A/en

1995-06-07 Priority claimed from US08/487,002 external-priority patent/US5710001A/en

1995-08-11 Application filed by Univ Utah Res Found, Us Health, Myriad Genetics Inc filed Critical Univ Utah Res Found

2002-03-11 Application granted granted Critical

2002-03-11 Publication of DK0705902T3 publication Critical patent/DK0705902T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Pathology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Medical Treatment And Welfare Office Work (AREA)
Apparatus For Radiation Diagnosis (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK95305601T 1994-08-12 1995-08-11 17q-koblet bryst- og ovariecancerprædisponeringsgen DK0705902T3 (da)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US28922194A	1994-08-12	1994-08-12
US30026694A	1994-09-02	1994-09-02
US30810494A	1994-09-16	1994-09-16
US34882494A	1994-11-29	1994-11-29
US40930595A	1995-03-24	1995-03-24
US48801195A	1995-06-07	1995-06-07
US08/483,554 US5747282A (en)	1994-08-12	1995-06-07	17Q-linked breast and ovarian cancer susceptibility gene
US08/487,002 US5710001A (en)	1994-08-12	1995-06-07	17q-linked breast and ovarian cancer susceptibility gene

Publications (1)

Publication Number	Publication Date
DK0705902T3 true DK0705902T3 (da)	2002-03-11

Family

ID=27575337

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK95305601T DK0705902T3 (da)	1994-08-12	1995-08-11	17q-koblet bryst- og ovariecancerprædisponeringsgen
DK95305602T DK0699754T3 (da)	1994-08-12	1995-08-11	Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK95305602T DK0699754T3 (da)	1994-08-12	1995-08-11	Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer

Country Status (15)

Country	Link
EP (2)	EP0705902B2 (da)
JP (1)	JP3399539B2 (da)
CN (1)	CN1159829A (da)
AT (2)	ATE209660T1 (da)
AU (2)	AU691331B2 (da)
CA (2)	CA2196795C (da)
DE (2)	DE69519834T3 (da)
DK (2)	DK0705902T3 (da)
ES (2)	ES2154712T5 (da)
FI (2)	FI970515A7 (da)
GR (1)	GR3035631T3 (da)
NO (2)	NO970626L (da)
NZ (1)	NZ291624A (da)
PT (2)	PT699754E (da)
WO (2)	WO1996005307A2 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995019369A1 (en)	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer
US6403303B1 (en)	1996-05-14	2002-06-11	Visible Genetics Inc.	Method and reagents for testing for mutations in the BRCA1 gene
US6083698A (en) *	1995-09-25	2000-07-04	Oncormed, Inc.	Cancer susceptibility mutations of BRCA1
US6130322A (en) *	1996-02-12	2000-10-10	Gene Logic, Inc.	Coding sequences of the human BRCA1 gene
US6951721B2 (en)	1996-02-12	2005-10-04	Gene Logic Inc.	Method for determining the haplotype of a human BRCA1 gene
US6838256B2 (en)	1996-02-12	2005-01-04	Gene Logic Inc.	Coding sequences of the human BRCA1 gene
US5654155A (en) *	1996-02-12	1997-08-05	Oncormed, Inc.	Consensus sequence of the human BRCA1 gene
US5891857A (en) *	1996-02-20	1999-04-06	Vanderbilt University	Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998005968A1 (en)	1996-08-02	1998-02-12	The Wistar Institute Of Anatomy And Biology	Brca1 associated protein (bap-1) and uses therefor
AU4586697A (en) *	1996-09-20	1998-04-14	Board Of Regents, The University Of Texas System	Compositions and methods comprising bard1 and other brca1 binding proteins
WO1998025125A2 (en) *	1996-12-03	1998-06-11	Swift Michael R	Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
US5965377A (en) *	1997-03-24	1999-10-12	Baystate Medical Center	Method for determining the presence of mutated BRCA protein
AU754748B2 (en) *	1997-06-04	2002-11-21	Rijksuniversiteit Te Leiden	A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
EP1003779A1 (en) *	1997-07-07	2000-05-31	Abbott Laboratories	Reagents and methods useful for detecting diseases of the breast
US5994096A (en) *	1997-07-25	1999-11-30	Smithkline Beecham Corporation	Regulator
US6492109B1 (en)	1997-09-23	2002-12-10	Gene Logic, Inc.	Susceptibility mutation 6495delGC of BRCA2
US6177410B1 (en)	1997-12-05	2001-01-23	Vanderbilt University	Therapeutic methods for prostate cancer
US6686163B2 (en)	1998-05-06	2004-02-03	Gene Logic Inc.	Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
US20030087250A1 (en) *	2001-03-14	2003-05-08	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CA2450663A1 (fr) *	2001-06-13	2002-12-19	Centre National De La Recherche Scientifique (C.N.R.S.)	Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
FR2826012B1 (fr) *	2001-06-13	2003-09-26	Centre Nat Rech Scient	Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
FR2836919B1 (fr) *	2002-03-05	2004-07-09	Centre Nat Rech Scient	Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
AU2003229953A1 (en)	2002-04-30	2003-11-17	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
JP5545690B2 (ja)	2003-12-01	2014-07-09	クドスファーマシューティカルズリミテッド	癌治療のためのｄｎａ損傷修復阻害剤
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
CN101037690B (zh) *	2006-03-16	2011-07-20	国家人口计生委科学技术研究所	具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
JP2009537154A (ja)	2006-05-18	2009-10-29	モレキュラープロファイリングインスティテュート，インコーポレイテッド	疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
CA2652167A1 (en)	2006-05-31	2007-12-06	Philip Jones	Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
TWI404716B (zh)	2006-10-17	2013-08-11	Kudos Pharm Ltd	酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
AR064777A1 (es)	2007-01-10	2009-04-22	Inst Di Reserche D Biolog Mole	Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
GB0716532D0 (en)	2007-08-24	2007-10-03	Angeletti P Ist Richerche Bio	Therapeutic compounds
CN101809017A (zh)	2007-09-14	2010-08-18	阿斯利康(瑞典)有限公司	酞嗪酮衍生物
RU2487868C2 (ru)	2007-10-17	2013-07-20	Кудос Фармасеутикалс Лимитед	4-[3-(4-циклопропанкарбонил-пиперазин-1-карбонил)-4-фтор-бензил]-2н-фталазин-1-он
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US8012976B2 (en)	2008-08-06	2011-09-06	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
WO2010019519A2 (en)	2008-08-10	2010-02-18	Kuakini Medical Center	Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity
ME02640B (me)	2008-10-07	2017-06-20	Kudos Pharm Ltd	Farmaceutske formulacije 514
CA2743211A1 (en)	2008-11-12	2010-05-20	Caris Life Sciences Luxembourg Holdings, S.A.R.L.	Methods and systems of using exosomes for determining phenotypes
WO2010101696A1 (en) *	2009-02-06	2010-09-10	Yale University	A snp marker of breast and ovarian cancer risk
WO2011007145A1 (en)	2009-07-15	2011-01-20	Astrazeneca Ab	Phthalazinone compound as parp inhibitor
EP2542696B1 (en)	2010-03-01	2016-09-28	Caris Life Sciences Switzerland Holdings GmbH	Biomarkers for theranostics
BR112012025593A2 (pt)	2010-04-06	2019-06-25	Caris Life Sciences Luxembourg Holdings	biomarcadores em circulação para doença
CN105525009B (zh) *	2016-01-26	2018-10-16	绍兴华因生物科技有限公司	检测杂合性brca1/2基因缺失的方法及所用引物
US20190375732A1 (en)	2018-05-14	2019-12-12	David Hung	Anti-cancer nuclear hormone receptor-targeting compounds
MX2021013774A (es)	2019-05-14	2021-12-10	Nuvation Bio Inc	Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
BR112022000534A2 (pt)	2019-07-19	2022-05-10	Astrazeneca Ab	Inibidores de parp1
US11952349B2 (en)	2019-11-13	2024-04-09	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
CN113388680B (zh) *	2020-03-14	2023-07-04	复旦大学附属妇产科医院	上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
KR102262529B1 (ko) *	2020-06-15	2021-06-09	연세대학교 산학협력단	Brca 변이성 난소암에 대한 진단 방법 및 이를 이용한 키트
US11795158B2 (en)	2020-06-25	2023-10-24	Astrazeneca Ab	Chemical compounds
KR20230084163A (ko)	2020-10-09	2023-06-12	아스트라제네카 유케이 리미티드	항체-약물 접합체와 parp1 선택적 억제제의 조합
EP4313991A1 (en)	2021-03-23	2024-02-07	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
US12006314B2 (en)	2021-05-03	2024-06-11	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
US20240366584A1 (en)	2021-06-21	2024-11-07	Tesaro, Inc.	Combination treatment of cancer with a parp inhibitor and a lipophilic statin
KR20240125925A (ko)	2021-11-18	2024-08-20	아스트라제네카 유케이 리미티드	항체-약물 콘쥬게이트와 parp1 선택적 억제제의 조합
AU2022422276B2 (en)	2021-12-21	2025-12-11	Astrazeneca Ab	Methods of treating brain tumours and neuroblastomas
EP4456922A1 (en)	2021-12-28	2024-11-06	AstraZeneca UK Limited	Combination of antibody-drug conjugate and atr inhibitor
US20250161305A1 (en)	2021-12-28	2025-05-22	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and rasg12c inhibitor
EP4493933A1 (en)	2022-03-16	2025-01-22	AstraZeneca UK Limited	A scoring method for an anti-trop2 antibody-drug conjugate therapy
US20250213556A1 (en)	2022-04-07	2025-07-03	Astrazeneca Ab	Combination therapy for treating cancer
JP2025511403A (ja)	2022-04-07	2025-04-15	アストラゼネカ・アクチエボラーグ	癌を治療するための併用療法
CA3254948A1 (en)	2022-04-07	2023-10-12	Astrazeneca Ab	Polytherapy for the treatment of cancer
JP2025522390A (ja)	2022-06-15	2025-07-15	アストラゼネカ・アクチエボラーグ	癌を処置するための併用療法
US20250360222A1 (en)	2022-07-28	2025-11-27	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
JP2025540063A (ja)	2022-11-30	2025-12-11	第一三共株式会社	抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用
TW202523359A (zh)	2023-10-24	2025-06-16	英商阿斯特捷利康英國股份有限公司	抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
WO2025120513A1 (en)	2023-12-05	2025-06-12	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
TW202545525A (zh)	2024-01-19	2025-12-01	瑞典商阿斯特捷利康公司	包含ａｚｄ５３０５之藥物組成物
WO2026052764A1 (en)	2024-09-06	2026-03-12	Astrazeneca Uk Limited	A scoring method for an anti-trop2 antibody drug conjugate therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4486530A (en)	1980-08-04	1984-12-04	Hybritech Incorporated	Immunometric assays using monoclonal antibodies
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
CA1188246A (en)	1981-08-31	1985-06-04	Jerry L. Gregory	Immobilized microbe recycle apparatus
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4868105A (en)	1985-12-11	1989-09-19	Chiron Corporation	Solution phase nucleic acid sandwich assay
IE61148B1 (en)	1988-03-10	1994-10-05	Ici Plc	Method of detecting nucleotide sequences
US5362623A (en) *	1991-06-14	1994-11-08	The John Hopkins University	Sequence specific DNA binding by p53
DE69032209T2 (de) *	1990-01-04	1998-12-03	The Johns Hopkins University, Baltimore, Md.	In menschlichen kolorektalkarzinomen fehlendes gen
EP0489149B1 (en) *	1990-06-27	2001-10-17	Princeton University	Probes for detecting mutant p53
AU1236092A (en) *	1991-01-04	1992-08-17	Baylor College Of Medicine	Tumor susceptible non-human animals
IL103059A0 (en)	1991-09-30	1993-02-21	Boehringer Ingelheim Int	Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
WO1994000764A1 (en) *	1992-06-26	1994-01-06	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES	The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) *	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer

1995
- 1995-08-11 AU AU33216/95A patent/AU691331B2/en not_active Expired
- 1995-08-11 DK DK95305601T patent/DK0705902T3/da active
- 1995-08-11 CA CA002196795A patent/CA2196795C/en not_active Expired - Lifetime
- 1995-08-11 EP EP95305601A patent/EP0705902B2/en not_active Expired - Lifetime
- 1995-08-11 PT PT95305602T patent/PT699754E/pt unknown
- 1995-08-11 AT AT95305601T patent/ATE209660T1/de not_active IP Right Cessation
- 1995-08-11 ES ES95305602T patent/ES2154712T5/es not_active Expired - Lifetime
- 1995-08-11 ES ES95305601T patent/ES2164136T5/es not_active Expired - Lifetime
- 1995-08-11 JP JP50751696A patent/JP3399539B2/ja not_active Expired - Lifetime
- 1995-08-11 CA CA002196790A patent/CA2196790C/en not_active Expired - Lifetime
- 1995-08-11 DE DE69519834T patent/DE69519834T3/de not_active Expired - Lifetime
- 1995-08-11 PT PT95305601T patent/PT705902E/pt unknown
- 1995-08-11 DE DE69524182T patent/DE69524182T3/de not_active Expired - Lifetime
- 1995-08-11 CN CN95195311.7A patent/CN1159829A/zh active Pending
- 1995-08-11 AU AU32428/95A patent/AU691958B2/en not_active Expired
- 1995-08-11 DK DK95305602T patent/DK0699754T3/da active
- 1995-08-11 WO PCT/US1995/010203 patent/WO1996005307A2/en not_active Ceased
- 1995-08-11 AT AT95305602T patent/ATE198623T1/de not_active IP Right Cessation
- 1995-08-11 WO PCT/US1995/010220 patent/WO1996005308A1/en not_active Ceased
- 1995-08-11 EP EP95305602A patent/EP0699754B2/en not_active Expired - Lifetime
- 1995-08-11 NZ NZ291624A patent/NZ291624A/en not_active IP Right Cessation
1997
- 1997-02-07 FI FI970515A patent/FI970515A7/fi unknown
- 1997-02-07 FI FI970514A patent/FI970514A7/fi not_active IP Right Cessation
- 1997-02-11 NO NO970626A patent/NO970626L/no not_active Application Discontinuation
- 1997-02-11 NO NO970625A patent/NO970625L/no not_active Application Discontinuation
2001
- 2001-03-23 GR GR20010400476T patent/GR3035631T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO970626D0 (no)	1997-02-11
CA2196795C (en)	2001-04-03
NZ291624A (en)	1998-07-28
WO1996005308A1 (en)	1996-02-22
AU3242895A (en)	1996-03-07
ATE209660T1 (de)	2001-12-15
DE69519834T3 (de)	2010-04-01
ES2164136T3 (es)	2002-02-16
DE69519834T2 (de)	2001-04-26
ATE198623T1 (de)	2001-01-15
JP2002502227A (ja)	2002-01-22
GR3035631T3 (en)	2001-06-29
EP0705902A1 (en)	1996-04-10
CA2196790C (en)	2000-10-10
FI970514A7 (fi)	1997-04-07
FI970515A0 (fi)	1997-02-07
AU691958B2 (en)	1998-05-28
EP0699754B2 (en)	2009-08-12
FI970515A7 (fi)	1997-04-07
DK0699754T3 (da)	2001-02-26
WO1996005307A2 (en)	1996-02-22
EP0699754A1 (en)	1996-03-06
NO970626L (no)	1997-04-14
FI970514A0 (fi)	1997-02-07
NO970625L (no)	1997-04-14
DE69524182D1 (de)	2002-01-10
AU3321695A (en)	1996-03-07
DE69524182T2 (de)	2002-05-29
CA2196795A1 (en)	1996-02-22
EP0699754B1 (en)	2001-01-10
AU691331B2 (en)	1998-05-14
WO1996005307A3 (en)	1996-03-14
JP3399539B2 (ja)	2003-04-21
DE69519834D1 (de)	2001-02-15
EP0705902B1 (en)	2001-11-28
EP0705902B2 (en)	2008-08-06
ES2154712T3 (es)	2001-04-16
NO970625D0 (no)	1997-02-11
ES2164136T5 (es)	2009-02-16
PT699754E (pt)	2001-04-30
CN1159829A (zh)	1997-09-17
ES2154712T5 (es)	2009-12-14
CA2196790A1 (en)	1996-02-22
PT705902E (pt)	2002-05-31
DE69524182T3 (de)	2009-07-09

Publication	Publication Date	Title
DK0705902T3 (da)	2002-03-11	17q-koblet bryst- og ovariecancerprædisponeringsgen
DK0705903T3 (da)	2001-08-27	Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen
NO982785L (no)	1998-08-17	Kromosom 13-koblet brystkreftmottagelighetsgen
ES2190466T3 (es)	2003-08-01	Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13.
AU6473598A (en)	1998-10-20	Method for determining the presence of mutated brca protein
WO1998025125A3 (en)	1999-08-05	Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
MX9701074A (es)	1998-02-28	Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (en)	2002-05-23	Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
ATE346150T1 (de)	2006-12-15	Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen
ES2104478T3 (es)	1997-10-01	Metodos de identificar linfocitos con fenotipos mutadores.